Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
By Jennifer B. Green, M. A. Bethel, P. Armstrong, John B. Buse, S. Engel, Jyotsna Garg, R. Josse, K. Kaufman, J. Koglin, S. Korn and 10 more. New England Journal of Medicine, 2015
2,285 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery
View Paper: https://www.semanticscholar.org/paper/5f5aabad35a6c6137b19d8640d5d6cafc91815e5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Endocrinology, Diabetes and Metabolism
- Juan José Marín-Peñalver
- Cristina Sevillano-Collantes
- Iciar Martín-Timón
- F. J. del Cañizo-Gómez
- John B. Buse
- V. Basevi
In Surgery
Citations in the corpus
- Inflammation and atherosclerosis: signaling pathways and therapeutic intervention (2022, background): “The cardiovascular safety of sitagliptin was validated in trials evaluating cardiovascular outcomes with sitagliptin.(348) Report showed that the risk of clinical adverse events did not increase during 18 weeks of sitagliptin treatment in patients in China, India, and South Korea.”
- Update on the treatment of type 2 diabetes mellitus. (2016, background): “…cardiovascular disease (history of major diseases of the coronary artery, ischemic cerebrovascular disease or peripheral arterial atherosclerotic disease) were randomized a group with sitagliptin and one with placebo, plus other diabetes medications (mainly metformin, sulfonylurea, insulin) [127] .”
- Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018, positive): “1% in both sitagliptinand placebo-treated patients (60).”